Men's Attitudes Toward Receiving the Human Papillomavirus Vaccine
- 1 October 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Lower Genital Tract Disease
- Vol. 12 (4) , 276-281
- https://doi.org/10.1097/lgt.0b013e318167913e
Abstract
To determine men's attitudes toward receiving the human papillomavirus (HPV) vaccine. Five hundred seventy-one men read a 1-page informational sheet about HPV and the HPV vaccine before completing a 29-item questionnaire. Descriptive statistics were calculated on all variables. Of these men, 33% wanted to receive the HPV vaccine, 27% did not, and 40% were undecided. The main reasons for wanting the vaccine included a desire to stay healthy (67.4%); prevention of cancer in my sexual partner(s) (52.9%); prevention of anal, penile, and head and neck cancer (41.0%); fear of cancer (33.4%); and prevention of genital warts (32.8%). Being in a monogamous relationship and not at risk (18.9%), not interested (13.8%), and not enough evidence yet to prove that it will help men (8.2%) were the main reasons for not wanting to be vaccinated. Although many men want to receive the HPV vaccine, more remain undecided. Pending favorable safety and efficacy results from a clinical trial for men, substantial factual education will likely convince many ambivalent men to receive the HPV vaccine.Keywords
This publication has 22 references indexed in Scilit:
- Anal squamous intraepithelial lesions and condyloma in HIV-infected heterosexual men, homosexual men and women: prevalence and associated factorsAIDS, 2007
- Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trialsThe Lancet, 2007
- Human Papillomavirus Prevalence and Type Distribution in Male Anogenital Sites and SemenCancer Epidemiology, Biomarkers & Prevention, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent Anogenital DiseasesNew England Journal of Medicine, 2007
- Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical LesionsNew England Journal of Medicine, 2007
- Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trialThe Lancet Oncology, 2005
- Sexually Transmitted Infection as a Cause of Anal CancerNew England Journal of Medicine, 1997
- Preferential Association of Human Papillomavirus With High-Grade Histologic Variants of Penile-Invasive Squamous Cell CarcinomaJNCI Journal of the National Cancer Institute, 1995
- The Detection of Human Papillomavirus Deoxyribonucleic Acid in Intraepithelial, in Situ, Verrucous and Invasive Carcinoma of the PenisJournal of Urology, 1995
- Human papillomavirus infection and intraepithelial, in situ, and invasive carcinoma of penisUrology, 1993